Identification of a compound that disrupts binding of amyloid-β to the prion protein using a novel fluorescencebased assay

Abstract

Background: The cellular form of the prion protein (PrPC) is implicated in Alzheimer disease as a receptor for amyloid-β (A β). Results: An assay was developed capable of identifying inhibitors of A β binding to PrPC. Conclusion: Chicago Sky Blue inhibits A β binding to PrPC. Significance: This is the first small molecule shown to disrupt the binding of A β; to PrPC.